ZX-8177 / Zenshine Pharma - LARVOL DELTA

ENPP1 inhibitor ZX-8177 in combination with chemotherapy or radiation exhibits synergistic anti-tumor effects via STING-mediated response (AACR 2023) - "Synergistic anti-tumor efficacy was observed in CT-26 model with the combination of Mitomycin C (0.5 mg/kg, BIW) and ZX-8177 (25 mg/kg, oral, BID), and in 4T1 and Pan02 models with the combination of Cisplatin (5 mg/kg, BIW) and ZX-8177 (25 mg/kg, oral, BID). Currently, ZX-8177 is under IND-enabling pre-clinical evaluation. First-in-human study of ZX-8177 is in planning as a single agent and combination therapies."

Combination therapy • Oncology • CD8 • CXCL10 • GZMA • GZMB • IFNB1 • STING